Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer Nature Pancreatic Cancer Specialists Getting a Jump on Daraxonrasib Medscape Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’ Chicago Tribune Stanford expands access to revolutionary pancreatic cancer drug Stanford Medicine Intermountain Health Oncologists Say New Drug to Treat Pancreatic Cancer May Be a “Game Changer” as 10 Intermountain Hospitals Join National Initiative Intermountain Health